| Project/Area Number |
15590062
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
ADACHI Tetsuo Gifu Pharmaceutical University, Laboratory of Clinical Pharmaceutics, Professor, 薬学部, 教授 (40137063)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HARA Hirokazu Gifu Pharmaceutical University, Laboratory of Clinical Pharmaceutics, Research assistant, 薬学部, 研究助手 (30305495)
INOUE Minoru Showa University, Fujigaoka Hospital, Division of Endocrinology and Department of Internal Medicine, Associate professor, 医学部, 講師 (30306998)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2004: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2003: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | Superoxide dismutase / Insulin resistance / Oxygen stress / Tumor necrosis factor-α / Transcription factors / Atherosclerosis / Pioglitazone / Extracellular-superoxide dismutase |
|---|
| Research Abstract |
Extracellular-superoxide dismutase (EC-SOD) is a secretory glycoprotein located in blood vessel walls at high levels and may be important in the antioxidant capability of vascular walls. The aim of this study was to assess plasma levels of EC-SOD and to evaluate the relationship of the EC-SOD level with insulin resistance in type 2 diabetic patients. We determined plasma EC-SOD in 122 patients and found for the first time that the EC-SOD level was strongly and positively related to adiponectin, and significantly and inversely related to fasting plasma glucose, body mass index (BMI) and homeostasis model assessment-insulin resistance index (HOMA-R). Administration of pioglitazone to 19 diabetic patients significantly increased the plasma levels of EC-SOD and adiponectin, while it decreased tumor necrosis factor-α (TNF-α). The present observations suggest that factors related to the pathogenesis of insulin resistance play an important role in the regulation of the plasma EC-SOD concentration.
Expression of EC-SOD is known to be regulated by numerous substances such as cytokines and vasoactive factors. Transcription factors such as CCAAT/enhancer-binding proteins (C/EBPs) and peroxisome proliferator-activated receptors (PPARs) are known to regulate genes associated with insulin resistance. We found that a C/EBPβ enhancer, prolactin, significantly induced the EC-SOD mRNA and protein levels in cultured fibroblast cell lines, but PPARγ ligands, pioglitazone and other thiazolidinedione agents did not. Deletion analysis of the EC-SOD promoter-luciferase construct showed that an important element responsible for prolactin is located between -242 and -178 in the promoter region of the EC-SOD gene in which a known C/EBPβ-binding site is located. Increasing the EC-SOD expression by treatment with ligands of transcription factors might be one approach to ameliorate the pathological conditions of insulin resistance.
|
